Followers | 1106 |
Posts | 279775 |
Boards Moderated | 10 |
Alias Born | 03/18/2011 |
Thursday, April 19, 2012 1:10:02 PM
http://www.google.com/finance?q=CYT
My stuff http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64797507
Never, invest with money you need to survive. Diversify, patience, set tight stops. $20 or less in commission fees is almost always cheaper than a 5-40%+ drop in share value.
Recent CYT News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:31:54 PM
- Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq • Business Wire • 03/07/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 11:11:17 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 12:36:52 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 12:14:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/14/2023 09:00:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:05:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 06:47:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/17/2023 09:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2023 09:01:01 PM
- Form DEFM14A - Definitive proxy statement relating to merger or acquisition • Edgar (US Regulatory) • 10/12/2023 08:14:58 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/12/2023 11:52:36 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 11:51:13 AM
- Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile • Business Wire • 10/12/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 08:00:08 PM
- Form PREM14A - Preliminary proxy statements relating to merger or acquisition • Edgar (US Regulatory) • 10/02/2023 08:44:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2023 08:01:32 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/30/2023 09:29:27 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/30/2023 02:37:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2023 02:22:12 PM
- Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution • Business Wire • 06/30/2023 12:00:00 PM
- Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile • Business Wire • 06/03/2023 01:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM